SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer Research suggests that overuse—including overscreening, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback